Long COVID Could Become a Widespread Post-pandemic Disease? A Debate on the Organs Most Affected
Overview
Authors
Affiliations
Long COVID is an emerging problem in the current health care scenario. It is a syndrome with common symptoms of shortness of breath, fatigue, cognitive dysfunction, and other conditions that have a high impact on daily life. They are fluctuating or relapsing states that occur in patients with a history of SARS-CoV-2 infection for at least 2 months. They are usually conditions that at 3 months after onset cannot be explained by an alternative diagnosis. Currently very little is known about this syndrome. A thorough review of the literature highlights that the cause is attributable to deposits of tau protein. Massive phosphorylation of tau protein in response to SARS-CoV-2 infection occurred in brain samples from autopsies of people previously affected with COVID-19. The neurological disorders resulting from this clinical condition are termed tauopathies and can give different pathological symptoms depending on the involved anatomical region of the brain. Peripheral small-fiber neuropathies are also evident among patients with Long COVID leading to fatigue, which is the main symptom of this syndrome. Certainly more research studies could confirm the association between tau protein and Long COVID by defining the main role of tau protein as a biomarker for the diagnosis of this syndrome that is widespread in the post-pandemic period.
Exploring the experiences of cognitive symptoms in Long COVID: a mixed-methods study in the UK.
Miller A, Song N, Sivan M, Chowdhury R, Burke M BMJ Open. 2025; 15(1):e084999.
PMID: 39863405 PMC: 11784330. DOI: 10.1136/bmjopen-2024-084999.
Khorram-Manesh A, Burkle Jr F, Goniewicz K Osong Public Health Res Perspect. 2024; 15(4):267-285.
PMID: 39039818 PMC: 11391372. DOI: 10.24171/j.phrp.2023.0372.
Gusev E, Sarapultsev A Int J Mol Sci. 2024; 25(12).
PMID: 38928096 PMC: 11204317. DOI: 10.3390/ijms25126389.
Szarvas Z, Fekete M, Szollosi G, Kup K, Horvath R, Shimizu M Geroscience. 2024; 46(5):4163-4183.
PMID: 38771423 PMC: 11336035. DOI: 10.1007/s11357-024-01179-z.
A Short Update on the Use of Monoclonal Antibodies in COVID-19.
Vitiello A, Sabbatucci M, Ponzo A, Salzano A, Zovi A AAPS J. 2024; 26(2):30.
PMID: 38443725 DOI: 10.1208/s12248-024-00904-y.